Sign inJoin waitlistJoin the waitlist

Nasser Hanna

Associate Division Director - Oncology · Indiana University School of Medicine

Credentials: · · ·

History

Indiana University School of Medicine
Present
Indiana University School of Medicine
Present
Indiana University School of Medicine
Present

Indiana University Medical Center
1998–2000
University of Iowa
1995–1998
University of Missouri School of Medicine
1991–1995

Research

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy
Journal of Clinical Oncology · 2004 · First of 20 authors · Corresponding · 2,017 citations
The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies
The Oncologist · 2009 · 584 citations
Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer
Journal of Clinical Oncology · 2006 · First of 13 authors · Corresponding · 509 citations

Lawrence Einhorn
63 papers
Shadia Jalal
31 papers
Nabil Adra
26 papers · 8 as a fellow
Greg Durm
24 papers · 4 as a fellow
Costantine Albany
17 papers
Kenneth Kesler
17 papers
RA
Rafat Ansari
13 papers
Gregory Masters
10 papers
Ramaswamy Govindan
9 papers
Thomas Birdas
9 papers
DuyKhanh Ceppa
8 papers
Nikhil Shukla
8 papers · 5 as a fellow

Grants

Indiana University Melvin and Bren Simon Comprehensive Cancer Center Support Grant
National Cancer Institute · P30
Project lead · $224.5K · Indiana University Indianapolis
1999–2024

Clinical trials

Using Circulating Tumor DNA to Personalize Duration of Consolidation Durvalumab
Principal investigator · Withdrawn · Phase 2
Indiana University
2024–2025
Serial Testing To Assess Cognitive Function In Cancer
Principal investigator · Terminated
Indiana University
2022–2024
Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select Stage III [Any T1-3 N1-2 and T4N0-2] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA)
Principal investigator · Active not recruiting · Phase 2
Nasser Hanna
2020–2026
Immunological Profile Changes In Patients With Advanced Non-Small Cell Lung Cancer
Principal investigator · Completed
Indiana University
2019–2022